Report: Optimizing Outsourcing in Early Small Molecule Drug Discovery
A recent survey commissioned by Dotmatics and conducted by C&EN BrandLab reveals that biotechs are increasingly outsourcing early small-molecule drug discovery to multiple CROs for expanded services like drug metabolism, pharmacokinetics, toxicology, and safety assessments, while both biotechs and CROs emphasize the critical need for improved data-management solutions to optimize collaboration.
Explore Trends and Needs in Biotech-CRO Collaborations
Outsourcing to contract research organizations (CROs) has been a strategic way for research companies to navigate a number of obstacles, including rising costs, waning funding options, and growing layoffs. There has been limited exploration of how to optimize early-discovery engagements, so Dotmatics commissioned C&EN BrandLab to survey Chemical & Engineering News readers about outsourced small-molecule-drug-discovery projects.
Survey Results
Biotechs are increasingly turning to multiple CROs for help in additional areas, such as drug metabolism and pharmacokinetic studies, as well as toxicology and safety assessment and more. Survey results also highlight the need to optimize biotech-CRO collaboration, with both bio-company and service-provider respondents citing a need for data-management solutions.
Read the full report to discover all of the insights from the survey, so you can put learnings into practice now.
Related
How Biotechs Can Streamline Multi-CRO Collaboration in Early Small Molecule Drug Discovery
A recent survey by C&EN BrandLab reveals that biotechs, facing funding challenges post-COVID, are increasingly outsourcing a broad range of early small molecule drug discovery tasks—beyond synthesis—to multiple CROs, with many engaging over five providers, highlighting a growing trend to optimize R&D by leveraging multi-CRO collaborations despite this area being less studied compared to clinical-phase outsourcing.
From Outsourcing Synthesis to Driving Innovation: How CROs Transformed Small Molecule R&D
The article explains how contract research organizations (CROs) transformed small molecule drug discovery by helping pharmaceutical and biotech companies control escalating R&D costs and overcome innovation slowdowns through outsourcing synthesis, expanding capacity, providing specialized expertise, and offering access to advanced technologies, thereby evolving from optional service providers into essential partners driving growth and innovation in the industry.
Three Real-World Examples of Smarter Biotech-CRO Outsourcing in Action
The article highlights how Dotmatics’ Biotech-CRO portal enhances early drug discovery outsourcing by enabling secure, efficient data exchange and project management, exemplified by Cereval’s use of the platform to streamline compound upload and registration between internal scientists and CROs while maintaining strict access controls.
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.
Webinar: Are you Ready for the Renaissance in Small Molecule Drug Discovery?
The webinar titled "Are you Ready for the Renaissance in Small Molecule Drug Discovery?" scheduled for February 2, 2023, features expert Haydn Boehm discussing challenges in small molecule drug discovery, emphasizing the importance of research collaboration, efficient data integration from multiple sources, and workflow optimization to reduce costs and accelerate finding better therapeutic candidates.
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.